Professor Andrew Carr was honoured in the 2025 King\u2019s Birthday Honours List being awarded an MBE for services to Orthopaedic Research and Training.
A new study to better understand the deadly bone cancer chondrosarcoma aims to reveal potential 'weak spots' of the disease with the ultimate goal of developing more effective treatments for patients.
Laura Coates presents the results from the 'SPEED' trial that found early use of biologic therapy or combination conventional DMARDs may be more effective than standard step-up care with methotrexate for psoriatic arthritis patients with poor prognostic factors.
NDORMS researchers have identified a primary source of inflammatory IL-17 driving spondyloarthritis, paving the way for the development of targeted therapies to treat the condition.
The Bone Cancer Research Trust and Sarcoma UK are joining forces to launch two groundbreaking research projects which could support the early diagnosis of primary bone cancer.
Professor of Orthopaedic Surgery Amar Rangan has been recognised as an exceptional health scientist in his election as a Fellow of the Academy of Medical Sciences.
A team at NDORMS, University of Oxford has successfully administered a pioneering treatment to a patient with XIAP deficiency, a rare genetic disorder.
Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer treatments. This study, published in Cell, demonstrates that engineering T-cells to express both a Chimeric Antigen Receptor (CAR) and a T-cell Receptor (TCR) can improve their ability to distinguish between cancerous and healthy tissues\u2014addressing a major challenge in current immunotherapy.
A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.
Dr Karthik Ramasamy and team will assess a new mass spectrometry-based monitoring technique for its ability to predict and identify early disease relapse.
Researchers at the University of Oxford have developed a new drug delivery system using ultrasound-activated nanoparticles to break through and destroy bacterial biofilms. This offers a promising solution that could address the global crisis of chronic antibiotic-resistant infections affecting hundreds of millions of people worldwide.
A recent study published in the American Journal of Gastroenterology investigates the incidence and survival rates of colorectal cancer (CRC) in the UK. The research offers healthcare decision-makers crucial insights for planning, management and screening for colorectal cancer.
The CONSORT 2025 statement, an updated guideline for reporting randomised trials is being simultaneously published in The BMJ, JAMA, The Lancet, Nature Medicine, and PLOS Medicine.
A new NDORMS study supports the hypothesis of immunity debt showing increases of influenza rates one year after global relaxation of COVID-19 restrictions. It highlights the need for proactive preparations in future pandemic response strategies.
The PROBAST+AI guidelines have been updated to provide clearer, more comprehensive standards for evaluating artificial intelligence (AI) models in healthcare research. Originally introduced to assess the risk of bias and the robustness of prediction models, they have been revised to address the growing importance of AI in healthcare decision-making.
New research from the Kennedy Institute has revealed how two important proteins, TBK1 and IKKe, play a crucial role in preventing premature cell death, which can lead to serious inflammation in the body. The findings are particularly relevant for people with a mutation in the TBK1 gene who often develop multiorgan inflammation caused by excessive cell death even in the absence of any infection.
![\"Professor](\"https://www.ndorms.ox.ac.uk/news/professor-andrew-carr-recognised-in-king2019s-birthday-honours/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n